دورية أكاديمية
Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapy.
| العنوان: | Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapy. |
|---|---|
| المؤلفون: | Gataa, Ithar, Mezquita, Laura, Rossoni, Caroline, Auclin, Edouard, Kossai, Myriam, Aboubakar Nana, Frank, Le Moulec, Sylvestre, Massé, Julie, Masson, Morgane, Radosevic-Robin, Nina, Alemany, Pierre, Rouanne, Mathieu, Bluthgen, Virginia, Hendriks, Lizza, Caramella, Caroline, Gazzah, Anas, Planchard, David, Pignon, Jean-Pierre, Besse, Benjamin, Adam, Julien |
| المساهمون: | UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (SLuc) Service de pneumologie |
| المصدر: | European journal of cancer, Vol. 145, p. 221-229 (2021) |
| بيانات النشر: | Elsevier Science Ltd |
| سنة النشر: | 2021 |
| المجموعة: | DIAL@UCL (Université catholique de Louvain) |
| مصطلحات موضوعية: | Biomarkers, Immune checkpoint inhibitor, Immunotherapy, Lung cancer, NSCLC, Nivolumab, Non–small cell lung cancer, Prognostic, TIL, Tumor-infiltrating lymphocytes |
| الوصف: | BACKGROUND: The established role of morphological evaluation of tumour-infiltrating lymphocytes (TILs) with immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC) is unknown. We aimed to determine TIL association with the outcome for ICIs and for chemotherapy in advanced NSCLC. METHODS: This is a multicenter retrospective study of a nivolumab cohort of 221 patients treated between November 2012 and February 2017 and a chemotherapy cohort of 189 patients treated between June 2009 and October 2016. Patients with available tissue for stromal TIL evaluation were analysed. The presence of a high TIL count (high-TIL) was defined as ≥10% density. The primary end-point was overall survival (OS). RESULTS: Among the nivolumab cohort, 64% were male, with median age of 63 years, 82.3% were smokers, 77% had performance status ≤1 and 63% had adenocarcinoma histology. High-TIL was observed in 22% patients and associated with OS (hazard ratio [HR] 0.48; 95% confidence interval [95% CI]: 0.28-0.81) and progression-free survival [PFS] (HR = 0.40; 95% CI: 0.25-0.64). Median PFS was 13.0 months (95% CI: 5.0-not reached) with high-TIL versus 2.2 months (95% CI: 1.7-3.0) with the presence of a low TIL count (low-TIL). Median OS for high-TIL was not reached (95% CI: 12.2-not reached) versus 8.4 months (95% CI: 5.0-11.6) in the low-TIL group. High-TIL was associated with the overall response rate (ORR) and disease control rate (DCR) (both, P < .0001). Among the chemotherapy cohort, 69% were male, 89% were smokers, 86% had performance status ≤1 and 90% had adenocarcinoma histology. High-TIL was seen in 37%. Median PFS and OS were 5.7 months (95% CI: 4.9-6.7) and 11.7 months (95% CI: 9.3-13.0), respectively, with no association with TILs. CONCLUSIONS: High-TIL was associated with favourable outcomes in a real-world immunotherapy cohort of patients with NSCLC, but not with chemotherapy, suggesting that TILs may be useful in selecting patients for immunotherapy. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 0959-8049 1879-0852 |
| العلاقة: | boreal:243587; http://hdl.handle.net/2078.1/243587Test; info:pmid/33516050; urn:ISSN:0959-8049; urn:EISSN:1879-0852 |
| DOI: | 10.1016/j.ejca.2020.10.017 |
| الإتاحة: | https://doi.org/10.1016/j.ejca.2020.10.017Test http://hdl.handle.net/2078.1/243587Test |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.7C33306D |
| قاعدة البيانات: | BASE |
| تدمد: | 09598049 18790852 |
|---|---|
| DOI: | 10.1016/j.ejca.2020.10.017 |